Back to Search
Start Over
Reducing Benzodiazepine Exposure by Instituting a Guideline for Dexmedetomidine Usage in the NICU
- Source :
- Pediatrics. 148
- Publication Year :
- 2021
- Publisher :
- American Academy of Pediatrics (AAP), 2021.
-
Abstract
- BACKGROUND Midazolam is a benzodiazepine sedative used in NICUs. Because benzodiazepine’s effects include respiratory depression and potential detrimental developmental effects, minimizing exposure could benefit neonates. Dexmedetomidine is routinely used for sedation in older pediatric populations. We implemented a quality improvement initiative with the aim of decreasing midazolam infusions by 20% through use of dexmedetomidine. METHODS A multidisciplinary committee created a sedation guideline that included standardized dexmedetomidine dosing escalation and weaning. Baseline data collection occurred from January 2015 to February 2018, with intervention from March 2018 to December 2019. Percentage of sedation episodes with dexmedetomidine initiated was followed as a process measure. Outcomes measures were percentage of eligible infants receiving midazolam infusions and midazolam-free days per sedation episode. Bradycardia with dexmedetomidine, unplanned extubation rates, and morphine dosage were monitored as balancing measures. RESULTS Our study included 434 episodes of sedation in 386 patients. Dexmedetomidine initiation increased from 18% to 49%. The intervention was associated with a significant reduction in midazolam initiation by 30%, from 95% to 65%, with special cause variation on statistical process control chart analysis. Midazolam-free days per sedation episode increased from 0.3 to 2.2 days, and patients receiving dexmedetomidine had lower midazolam doses (1.3 mg/kg per day versus 2.2 mg/kg per day, P = 5.97 × 10−04). Bradycardia requiring discontinuation of dexmedetomidine, unplanned extubation rates, and morphine doses were unchanged. CONCLUSIONS Implementation of a quality improvement initiative was successful in reducing the percentage of patients receiving midazolam infusions and increased midazolam-free days per sedation episode, revealing an overall reduction in benzodiazepine exposure while maintaining adequate sedation.
- Subjects :
- Bradycardia
Time Factors
medicine.drug_class
Midazolam
Sedation
Gestational Age
Drug Administration Schedule
Benzodiazepines
Child Development
Intensive Care Units, Neonatal
Outcome Assessment, Health Care
medicine
Humans
Hypnotics and Sedatives
Dosing
Dexmedetomidine
Patient Care Team
Benzodiazepine
Morphine
Drug Substitution
business.industry
Infant, Newborn
Guideline
Hospitals, Pediatric
Quality Improvement
Respiration, Artificial
Discontinuation
Analgesics, Opioid
Anesthesia
Pediatrics, Perinatology and Child Health
Airway Extubation
Intensive Care, Neonatal
Hypotension
medicine.symptom
Respiratory Insufficiency
business
Boston
medicine.drug
Subjects
Details
- ISSN :
- 10984275 and 00314005
- Volume :
- 148
- Database :
- OpenAIRE
- Journal :
- Pediatrics
- Accession number :
- edsair.doi.dedup.....69340d45be866f4be1590f8c9e67e732
- Full Text :
- https://doi.org/10.1542/peds.2020-041566